Resources Repository
-
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Health Outcomes | State-Transition | Dynamic Transmission | Microsimulation | Infectious Diseases | Child/Nutrition | Economics/Finance | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Priority Setting/Ethics | Economics/Finance | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Europe -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Mathematical Models | Dynamic Transmission | Infectious Diseases | Child/Nutrition | Global Governance | Climate/Environment | Economics/Finance | Latin America & Caribbean -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Cost-Effectiveness Analysis | Health/Medicine | North America | Health Systems | Preferences/Values | Health Outcomes | Mathematical Models | Technology Assessment | Science/Technology | Europe -
ArticlePublication 2016An Economic Evaluation of the PEN Program in Indonesia
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) …
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) introduced the Package of Essential Noncommunicable disease (PEN) interventions. Several countries, including Indonesia, implemented the PEN program. To assess the value of the investment in the current program, an economic evaluation of the program was conducted with collaboration between the Ministry of Health in Indonesia, the WHO, and the International Decision Support Initiative (iDSI). This study evaluated the delivery of…
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Priority Setting/Ethics | Technology Assessment | Chronic Disease/Risk | Economics/Finance | Government/Law -
ArticlePublication 2016Helmet Regulation in Vietnam: Impact on Health, Equity and Medical Impoverishment
This study performed a retrospective extended cost-effectiveness analysis simulation study of Vietnam's 2007 comprehensive motorcycle …
This study performed a retrospective extended cost-effectiveness analysis simulation study of Vietnam's 2007 comprehensive motorcycle helmet policy. Modeling results showed that following its introduction, the helmet policy likely prevented approximately 2,200 deaths and 29,000 head injuries, saved individuals US$18 million in acute care costs and averted US$31 million in income losses. From a societal perspective, such a comprehensive helmet policy would have saved $11 000 per averted death or $830 per averted non-fatal injury.
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Injuries/Accidents -
ArticlePublication 2016Extended CEA: Home-Based Neonatal Care in Rural India
This chapter examines the health, economic benefits, and government costs associated with scaling up a …
This chapter examines the health, economic benefits, and government costs associated with scaling up a publicly financed home-based neonatal care package in rural India. This extended cost-effectiveness analysis considers two intervention scenarios against a baseline of no home-based neonatal care, both of which would utilize community health workers - one would provide coverage to approximately 7 out of 10 rural newborns, and the other would provide coverage to 9 out of 10 rural newborns.
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Priority Setting/Ethics | Child/Nutrition | Social Determinants | Economics/Finance -
ArticlePublication 2015Thirty Years of Vaccination in Vietnam: Impact and Cost-Effectiveness
Countries like Vietnam transitioning to middle-income status increasingly bear the cost of both existing and …
Countries like Vietnam transitioning to middle-income status increasingly bear the cost of both existing and new vaccines. However, the impact and cost-effectiveness of the Expanded Programme on Immunization (EPI) as a whole has never been assessed on a country level. Data on vaccine-preventable disease incidence and mortality from Vietnam's national surveillance was analyzed to estimate the likely impact that vaccination in 1980–2010 may have had. The same data were separately analyzed using the Lives Saved Tool…
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Infectious Diseases | Economics/Finance -
ArticlePublication 2015Publicly Financed HPV Vaccination in China: Extended Cost-Effectiveness Analysis
This extended cost-effectiveness analysis evaluates public financing of HPV vaccination in China to prevent cervical cancer. Authors …
This extended cost-effectiveness analysis evaluates public financing of HPV vaccination in China to prevent cervical cancer. Authors estimated the distribution of deaths averted by income quintile, compared vaccination paired with screening against current practice. They estimated reductions in cervical cancer incidence, net costs to the government, and patient cost savings, as well as the incremental government health care costs per death averted. When the cost per HPV vaccination is less than US$50 per vaccinated girl, vaccination was…
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Priority Setting/Ethics | Microsimulation | Chronic Disease/Risk | Economics/Finance